PLCD1 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P51178 |
---|---|
Clone Names | 100311256 |
Gene ID | 5333 |
---|---|
Other Names | 1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase delta-1, Phosphoinositide phospholipase C-delta-1, Phospholipase C-III, PLC-III, Phospholipase C-delta-1, PLC-delta-1, PLCD1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PLCD1 (HGNC:9060) |
---|---|
Function | The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes (PubMed:9188725). Essential for trophoblast and placental development (By similarity). Binds phosphatidylinositol 4,5-bisphosphate (PubMed:7890667, PubMed:9188725). |
Tissue Location | Strongly expressed in lung, liver and heart. Also expressed at least in pancreas, kidney, skeletal muscle, placenta and brain. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Phosphoinositide-specific phospholipase C (PLC) acts as asignal transducer that generates 2 second messengers,diacylglycerol and inositol 1,4,5-trisphosphate, by hydrolyzinginositol phospholipids. PLC comprises a diverse family of enzymesthat differ in structure and tissue distribution (Berridge, 1993[PubMed 8381210]).
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Saus, E., et al. J Psychiatr Res 44(14):971-978(2010)Guo, Y., et al. J. Biol. Chem. 285(32):24999-25008(2010)Segat, L., et al. Vaccine 28(10):2201-2206(2010)Godin, C.M., et al. Mol. Pharmacol. 77(3):388-395(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.